biguanides has been researched along with Insulin Sensitivity in 49 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study represents a new insight into the Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 study population at inclusion." | 7.71 | Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. ( André, P; Bard, JM; Charles, MA; Eschwege, E; Fruchart, JC; Juhan-Vague, I; Safar, M; Vague, P, 2001) |
| "The aim of the present study was to evaluate the relationship of C-peptide and the C-peptide/bloodsugar ratio with clinical/biochemical variables presenting a well-known association with insulin resistance in NIDDM patients in acceptable control, obtained without the use of exogenous insulin." | 7.69 | Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. ( Acosta, D; Astorga, R; García de Pesquera, F; Losada, F; Morales, F; Pumar, A; Relimpio, F, 1997) |
| "The effect of short-term treatment with biguanides on the insulin sensitivity (KITT) of maturity onset diabetics was tested by means of an insulin tolerance test." | 7.66 | [The effect of biguanides on insulin sensitivity of maturity onset diabetics (author's transl)]. ( Braunsteiner, H; Lisch, HJ; Sailer, S, 1980) |
| " Metformin, an antihyperglycemic drug of the biguanide class, may be effective in subjects with IGT by reducing hepatic glucose output, enhancing insulin sensitivity, or through other mechanisms such as weight loss." | 4.79 | [Drug therapy in subjects with impaired glucose tolerance]. ( Kawamori, R; Yoshii, H, 1996) |
| "The present study represents a new insight into the Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 study population at inclusion." | 3.71 | Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. ( André, P; Bard, JM; Charles, MA; Eschwege, E; Fruchart, JC; Juhan-Vague, I; Safar, M; Vague, P, 2001) |
| "The aim of the present study was to evaluate the relationship of C-peptide and the C-peptide/bloodsugar ratio with clinical/biochemical variables presenting a well-known association with insulin resistance in NIDDM patients in acceptable control, obtained without the use of exogenous insulin." | 3.69 | Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. ( Acosta, D; Astorga, R; García de Pesquera, F; Losada, F; Morales, F; Pumar, A; Relimpio, F, 1997) |
| "The effect of short-term treatment with biguanides on the insulin sensitivity (KITT) of maturity onset diabetics was tested by means of an insulin tolerance test." | 3.66 | [The effect of biguanides on insulin sensitivity of maturity onset diabetics (author's transl)]. ( Braunsteiner, H; Lisch, HJ; Sailer, S, 1980) |
| "The management of type 1 diabetes remains a challenge for clinicians." | 2.52 | The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. ( Davis, SN; Munir, KM, 2015) |
| "Current strategies for the treatment of type 2 diabetes mellitus promote individualized plans to achieve target glucose levels on a patient-by-patient basis while minimizing treatment related risks." | 2.49 | Complications of diabetes therapy. ( Corathers, SD; Peavie, S; Salehi, M, 2013) |
| "Nonalcoholic steatohepatitis (NASH) once considered a benign process is now known to lead to progressive fibrosis and cirrhosis." | 2.43 | [Drug therapy for non-alcoholic steatohepatitis]. ( Hibi, T; Tomita, K, 2006) |
| "Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements." | 2.42 | Insulin sensitizers. ( Basu, A; Kudva, YC; Zangeneh, F, 2003) |
| "In patients with type 2 diabetes mellitus, the traditional method of initiating therapy with a sulfonylurea and increasing the dosage until maximum levels are reached before adding an insulin-sensitizing agent has persisted and should be re-evaluated." | 2.42 | A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches. ( Bell, DS, 2004) |
| "Because insulin resistance is an underlying pathologic defect in patients with type 2 diabetes, agents that increase insulin sensitivity should be used early in the course of therapy." | 2.41 | Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus. ( Weissman, P, 2002) |
| "Optimal treatment for type 2 diabetes mellitus should aim to improve insulin resistance and the associated cardiovascular risk factors in addition to achieving glycaemic control." | 2.41 | Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? ( Campbell, IW, 2000) |
| "Hyperglycemia in patients with type 2 diabetes mellitus is caused by peripheral insulin resistance, which results in decreased insulin-mediated glucose disposal and increased endogenous glucose production, and inadequate insulin secretion." | 2.41 | [Clinical difference between thiazolidinediones and biguanides]. ( Hotta, N, 2001) |
| "Biguanides have been used in treatment of diabetes mellitus for over 30 years now." | 2.40 | [Value of biguanide in therapy of diabetes mellitus]. ( Haupt, E; Panten, U, 1997) |
| " Despite historic reliance on these agents to treat type 2 diabetes, long-term use of SUs may desensitize beta cells." | 2.40 | Effects of current therapeutic interventions on insulin resistance. ( Kobayashi, M, 1999) |
| "Insulin resistance is a major pathogenesis underlying the development of hyperglycemia and cardiovascular diseases in type 2 diabetes." | 1.36 | [Difference between biguanide and thiazolidinedione, and the significance of combination therapy of biguanide and thiazolidinedione]. ( Masuda, K; Terauchi, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (28.57) | 18.7374 |
| 1990's | 7 (14.29) | 18.2507 |
| 2000's | 20 (40.82) | 29.6817 |
| 2010's | 8 (16.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbas, SY | 2 |
| Basyouni, WM | 2 |
| El-Bayouk, KAM | 1 |
| Tohamy, WM | 1 |
| Aly, HF | 1 |
| Arafa, A | 1 |
| Soliman, MS | 1 |
| Gutiérrez-Lara, EJ | 1 |
| Navarrete-Vázquez, G | 1 |
| Sánchez-López, A | 1 |
| Centurión, D | 1 |
| Corathers, SD | 1 |
| Peavie, S | 1 |
| Salehi, M | 1 |
| Munir, KM | 1 |
| Davis, SN | 1 |
| El-Bayouki, KA | 1 |
| Abdel-Rahman, RF | 1 |
| Bourron, O | 1 |
| Daval, M | 1 |
| Hainault, I | 1 |
| Hajduch, E | 1 |
| Servant, JM | 1 |
| Gautier, JF | 1 |
| Ferré, P | 1 |
| Foufelle, F | 1 |
| Yasuda, H | 1 |
| Nagata, M | 1 |
| Hara, K | 1 |
| Moriyama, H | 1 |
| Yokono, K | 1 |
| Masuda, K | 1 |
| Terauchi, Y | 1 |
| Weissman, P | 1 |
| Maruyama, T | 1 |
| Okubo, M | 1 |
| Yamane, K | 1 |
| Kohno, N | 1 |
| Mori, Y | 1 |
| Sekihara, H | 1 |
| Yamasaki, Y | 1 |
| Kuroda, A | 1 |
| Kitaoka, H | 1 |
| Kotake, H | 1 |
| Zangeneh, F | 1 |
| Kudva, YC | 1 |
| Basu, A | 1 |
| CARLETTI, D | 1 |
| Bell, DS | 1 |
| Ishida, W | 1 |
| Satoh, J | 1 |
| Kume, A | 1 |
| Miyazaki, T | 1 |
| Daida, H | 1 |
| Hankó, B | 1 |
| Tukarcs, E | 1 |
| Kumli, P | 1 |
| Vincze, Z | 1 |
| Bertrand, L | 1 |
| Ginion, A | 1 |
| Beauloye, C | 1 |
| Hebert, AD | 1 |
| Guigas, B | 1 |
| Hue, L | 1 |
| Vanoverschelde, JL | 1 |
| Tomita, K | 1 |
| Hibi, T | 1 |
| Galindo García, CG | 1 |
| Vega Arias, Mde J | 1 |
| Hernández Marín, I | 1 |
| Ayala, AR | 1 |
| Scemons, D | 1 |
| Jellinger, PS | 1 |
| Levin, PA | 1 |
| McLaughlin, J | 1 |
| Kowarski, AA | 1 |
| Durán García, S | 1 |
| Hernández Herrero, C | 1 |
| Schernthaner, G | 1 |
| Prager, R | 1 |
| Lisch, HJ | 1 |
| Sailer, S | 1 |
| Braunsteiner, H | 1 |
| Kawamori, R | 1 |
| Yoshii, H | 1 |
| Relimpio, F | 1 |
| Losada, F | 1 |
| Pumar, A | 1 |
| García de Pesquera, F | 1 |
| Morales, F | 1 |
| Acosta, D | 1 |
| Astorga, R | 1 |
| Haupt, E | 1 |
| Panten, U | 1 |
| Sakamoto, N | 1 |
| Uno, T | 1 |
| Ishii, J | 1 |
| Inoue, I | 1 |
| Kasuga, M | 1 |
| Hunabiki, A | 1 |
| Morita, S | 1 |
| Campbell, IW | 1 |
| Kobayashi, M | 1 |
| Bard, JM | 1 |
| Charles, MA | 1 |
| Juhan-Vague, I | 1 |
| Vague, P | 1 |
| André, P | 1 |
| Safar, M | 1 |
| Fruchart, JC | 1 |
| Eschwege, E | 1 |
| Hotta, N | 1 |
| Blagosklonnaia, IaV | 1 |
| Zalevskaia, AG | 1 |
| Krasi'lnikova, EI | 1 |
| Ostroukhova, EN | 1 |
| Dani'lchenko, AR | 1 |
| Bornemisza, P | 1 |
| Hockaday, TD | 1 |
| Parodi, FA | 1 |
| Klein, W | 1 |
| Hole, P | 1 |
| Dietzmann, HB | 1 |
| Buding, A | 1 |
| Wright, AD | 1 |
| Hartog, M | 1 |
| Palter, H | 1 |
| Tevaarwerk, G | 1 |
| Doyle, FH | 1 |
| Arnot, R | 1 |
| Joplin, GF | 1 |
| Fraser, TR | 1 |
| Takeda, M | 1 |
| Nishikawa, K | 1 |
| Miki, S | 1 |
| Fujii, Y | 1 |
| Tatsumi, K | 1 |
| Raptis, S | 1 |
| Rothenbuchner, G | 1 |
| Pfeiffer, EF | 1 |
| Davidoff, FF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| New Electrophoretic Approaches in Studies of Obesity and Diabetes[NCT03189732] | 10 participants (Actual) | Interventional | 2015-10-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
28 reviews available for biguanides and Insulin Sensitivity
| Article | Year |
|---|---|
Complications of diabetes therapy.
Topics: Biguanides; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Huma | 2013 |
The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.
Topics: Biguanides; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors | 2015 |
Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus.
Topics: Administration, Oral; Antihypertensive Agents; Biguanides; Diabetes Mellitus, Type 2; Glucosamine; H | 2002 |
[Pharmacotherapies for type 1 diabetes mellitus].
Topics: Adjuvants, Immunologic; Animals; Biguanides; Chaperonin 60; Diabetes Mellitus, Type 1; Glycoside Hyd | 2002 |
[Pharmacologic profile of oral antidiabetic agents].
Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hy | 2002 |
[Adverse effects of oral hypoglycemic agents].
Topics: Acarbose; Administration, Oral; Biguanides; Cyclohexanes; Drug Interactions; Glycoside Hydrolase Inh | 2002 |
[Adverse effect of biguanides].
Topics: Acidosis, Lactic; Biguanides; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Humans; Hypoglyc | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug T | 2002 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism | 2002 |
Insulin sensitizers.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 2003 |
A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches.
Topics: Animals; Benzamides; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Glyc | 2004 |
[Characteristic of metformin for treatment of impaired glucose tolerance].
Topics: Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Glucose; Glucose Intolerance; Humans; Hypog | 2005 |
[Treatment for coronary artery disease patients with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Coronary Artery Bypass; Coronary Artery Disease; Glucose Intolerance; Glycosid | 2005 |
[Drug therapy for non-alcoholic steatohepatitis].
Topics: Antihypertensive Agents; Antioxidants; Biguanides; Fatty Liver; Humans; Hypolipidemic Agents; Insuli | 2006 |
[Mechanism of action of insulin sensitizer agents in the treatment of polycystic ovarian syndrome].
Topics: Biguanides; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Tria | 2007 |
Are you up-to-date on diabetes medications?
Topics: Amyloid; Benzamides; Biguanides; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2007 |
Metabolic consequences of hyperglycemia and insulin resistance.
Topics: Biguanides; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Dyslipidemias; Fatty Acids, No | 2007 |
[Physiologic and physiopathologic implications of insulin-receptor interaction (II). Pathologic situations in which changes in insulin-receptor interaction are detected].
Topics: Acanthosis Nigricans; Animals; Biguanides; Child; Diabetes Complications; Diabetes Mellitus, Type 1; | 1984 |
[Insulin receptor and postreceptor disorders: significance for the development and therapy of carbohydrate metabolic disorders].
Topics: Autoantibodies; Biguanides; Body Weight; Carbohydrate Metabolism, Inborn Errors; Diabetes Mellitus; | 1984 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase | 1996 |
[Value of biguanide in therapy of diabetes mellitus].
Topics: Biguanides; Blood Glucose; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 1997 |
[Oral hypoglycemic agents--overview].
Topics: Acarbose; Administration, Oral; Biguanides; Chromans; Glycoside Hydrolase Inhibitors; Humans; Hypogl | 1997 |
[Measures to meet the side effects of the orally administered antihyperglycemic drugs].
Topics: Acarbose; Administration, Oral; Animals; Biguanides; Cardiovascular System; Chromans; Drug Interacti | 1997 |
[Etiology and therapy of insulin resistance].
Topics: Animals; Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertens | 1999 |
Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Risk Fac | 2000 |
Effects of current therapeutic interventions on insulin resistance.
Topics: Biguanides; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; Enzyme Inhibitors; Exercise; Glycosi | 1999 |
[Clinical difference between thiazolidinediones and biguanides].
Topics: Biguanides; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2001 |
Diabetes mellitus.
Topics: Alcohol Drinking; Anxiety; Biguanides; Blood Glucose; Blood Pressure; Body Weight; Cholesterol, Diet | 1974 |
21 other studies available for biguanides and Insulin Sensitivity
| Article | Year |
|---|---|
New Biguanides as Anti-Diabetic Agents Part I: Synthesis and Evaluation of 1-Substituted Biguanide Derivatives as Anti-Diabetic Agents of Type II Diabetes Insulin Resistant.
Topics: Animals; Biguanides; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents | 2017 |
Pharmacological evaluation of metformin and N-benzylbiguanide, a novel analogue of metformin, on the vasopressor responses to adrenergic system stimulation in pithed rats with fructose-induced insulin resistance.
Topics: Adrenergic Agonists; Animals; Biguanides; Blood Glucose; Blood Pressure; Fructose; Heart Rate; Hemod | 2017 |
Synthesis and Evaluation of 1-Substituted-Biguanide Derivatives as Anti-Diabetic Agents for Type II Diabetes Insulin Resistant.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biguanides; Blood Glucose; Cholesterol; | 2016 |
Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adenylate Kinase; Adipocytes; Adipose Tissue; Adren | 2010 |
Biguanide, but not thiazolidinedione, improved insulin resistance in Werner syndrome.
Topics: Biguanides; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Middle Aged; Thiazolidinediones | 2010 |
[Difference between biguanide and thiazolidinedione, and the significance of combination therapy of biguanide and thiazolidinedione].
Topics: Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Insulin Resistance; Thiazo | 2010 |
[CHLORPROPAMIDE AND PHENETHYLBIGUANIDE ASSOCIATED WITH INSULIN THERAPY IN SOME CASES OF INSULIN RESISTANCE].
Topics: Antimalarials; Biguanides; Chlorpropamide; Diabetes Mellitus; Guanidine; Guanidines; Humans; Insulin | 1965 |
Antidiabetic drug utilization in hungary.
Topics: Acarbose; Biguanides; Diabetes Mellitus; Dietary Carbohydrates; Drug Therapy, Combination; Drug Util | 2005 |
AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B.
Topics: AMP-Activated Protein Kinases; Animals; Biguanides; Cells, Cultured; Dose-Response Relationship, Dru | 2006 |
Diabetes mellitus: customizing management.
Topics: Adult; Aging; Biguanides; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty | 1984 |
[The effect of biguanides on insulin sensitivity of maturity onset diabetics (author's transl)].
Topics: Aged; Biguanides; Blood Glucose; Diabetes Mellitus; Female; Humans; Insulin; Insulin Resistance; Mal | 1980 |
Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients.
Topics: Administration, Oral; Aged; Apolipoproteins; Biguanides; Blood Glucose; Blood Pressure; Body Constit | 1997 |
Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study.
Topics: Abdomen; Adult; Aged; Biguanides; Biomarkers; Cardiovascular Diseases; Endothelium, Vascular; Female | 2001 |
[Biguanide derivatives in diabetes mellitus].
Topics: Adolescent; Adult; Biguanides; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, C | 1989 |
[Treatment possibilities of insulin resistance].
Topics: Adrenocorticotropic Hormone; Adult; Biguanides; Diabetes Mellitus; Drug Hypersensitivity; Female; Gl | 1969 |
[Criteria for the choice of antidiabetic treatment].
Topics: Biguanides; Carbutamide; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance | 1969 |
[Resistance to insulin, brittle abetes and reaction of the fasininsulin activity during the administration of biguanides].
Topics: Aged; Biguanides; Blood Flow Velocity; Diabetes Mellitus; Female; Humans; Insulin; Insulin Resistanc | 1969 |
The use of yttrium 90 implantation in the treatment of acromegaly.
Topics: Acromegaly; Biguanides; Cerebrospinal Fluid Rhinorrhea; Cloxacillin; Diabetes Insipidus; Gold Isotop | 1970 |
[Clinical studies on insulin-resistant diabetes and insulin-rebound diabetes].
Topics: Biguanides; Blood Glucose; Blood Protein Electrophoresis; Blood Proteins; Diabetes Mellitus; Humans; | 1970 |
[Progress in the therapy of diabetes].
Topics: Adrenal Cortex Hormones; Adult; Aged; Aminocaproates; Animals; Biguanides; Blood Glucose; Child; Dia | 1971 |
Oral hypoglycemic agents and the mechanism of diabetes mellitus.
Topics: Biguanides; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resistance | 1968 |